What is the market's earnings forecast for Merck next quarter?

Did Merck beat or miss consensus estimates last quarter?

What were the key takeaways from Merck’s earnings call?

What is Merck's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Merck year over year?

What were the key takeaways from Merck's earnings call?

What factors drove the changes in Merck's revenue and profit?

What guidance did Merck's management provide for the next earnings period?

- **Revenue Growth**: Q4 2025 revenue $16.4B (+5% YoY), driven by KEYTRUDA (+5%), new launches (WINREVAIR, OHTUVAYRE), and Animal Health (+6%).
- **Pipeline Momentum**: $70B+ pipeline by mid-2030s includes enlicitide ($5B+), MK-1406 ($5B+), and HIV组合疗法. 2026 guidance: $65.5-67B revenue (+1-3%).
- **Strategic Acquisitions**: $9B Cidara charge for MK-1406; Verona Pharma acquisition expands respiratory portfolio.
- **Clinical Milestones**: Enlicitide Phase III data shows LDL-C reduction; sac-TMT in 16 Phase III trials; HIV dual regimen non-inferior to Biktarvy.

**【CEO Summary Section】**
- Total Q4 2025 revenue: $16.4 billion (+5% YoY). KEYTRUDA family sales: $8.4 billion (+5% YoY), driven by earlier-stage cancer use and U.S. QLEX launch ($35M). New product launches (WINREVAIR, OHTUVAYRE) and Animal Health (+6%) offset GARDASIL decline (-35% due to China/Japan). 2026 guidance: $65.5-67B revenue (+1-3%), including $70B+ pipeline opportunity by mid-2030s. Key growth drivers: enlicitide (PCSK9 inhibitor), MK-1406 (influenza预防药), and HIV组合疗法.

**【CFO Financial Commentary】**
- Q4 2025 non-GAAP EPS: $2.04. Gross margin: 79.7% (down 1.1pts due to inventory charges). Operating expenses: $6.8B (flat ex. $150M Cidara acquisition charge). 2026 guidance: EPS $5-5.15 (midpoint $5.08), including $3.65B one-time Cidara charge. Capital allocation: $3B+ share buybacks, dividend growth, and disciplined M&A.

**【R&D Pipeline Updates】**
- **Cardiometabolic:** Enlicitide Phase III data shows LDL-C reduction; MK-1406 (Cidara) Phase III enrollment complete. **Oncology:** KEYTRUDA QLEX adoption expected 30-40% by 2028. Sac-TMT (TROP2 ADC) in 16 Phase III trials. **HIV:** Doravirine/islatravir Phase III non-inferior to Biktarvy; islatravir/lenacapavir weekly regimen in Phase III. **Respiratory:** WINREVAIR expanded EU indication; ENFLONSIA Phase III ongoing.

**【Q&A Highlights】**
- **Flu Season Impact:** Strong flu season may accelerate MK-1406 event rates, but trial completion remains data-driven. **TROP2 Strategy:** Sac-TMT differentiated by linker/payload; 16 Phase III trials vs. competitors. **KEYTRUDA IP:** Patents extend to 2029; QLEX adoption strategy unchanged despite IRA. **HIV Regimens:** Dual therapy ( doravirine/islatravir) avoids INSTI; weekly regimen with Gilead in Phase III.

Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: Q3 2025 revenue $17.3 billion (+4% YoY), driven by 8% oncology sales growth and new product launches like ENFLONSIA ($79M initial stocking). Early-stage KEYTRUDA sales exceed 25% of total.
- **Pipeline Breakthroughs**: 80 Phase III trials advancing, including enlicitide (PCSK9 inhibitor) Phase III success and tulisokibart expansion into dermatology. Verona Pharma acquisition adds $50B+ pipeline value.
- **Strategic Investments**: $70B U.S. manufacturing expansion. 2026 operating expenses $25.9-26.4B to fund pipeline, offsetting headwinds from generic entries.
- **Key Launches**: KEYTRUDA QLEX targeting 30-40% patient adoption by 2026. ENFLONSIA poised for significant RSV season impact. OHTUVAYRE and BRAVECTO QUANTUM driving 2026 growth.

**【CEO Summary Section】**
- **Revenue Growth**: Total revenue for Q3 2025 was $17.3 billion, up 4% year-over-year (3% excluding FX). Oncology sales grew 8% to $8.1 billion, driven by KEYTRUDA and WELIREG. Early-stage cancer treatments contributed over half of KEYTRUDA's growth.
- **Pipeline Momentum**: 80 Phase III trials across oncology, immunology, and cardiovascular diseases. Notable advancements include enlicitide (PCSK9 inhibitor) and tulisokibart (TL1A targeting ADCs). Verona Pharma acquisition adds $50 billion+ commercial potential by mid-2030s.
- **Strategic Initiatives**: $70 billion+ U.S. manufacturing investments. Engaged with U.S. administration to balance patient affordability with fair foreign pricing. KEYTRUDA QLEX subcutaneous injection launched, targeting 30-40% patient adoption within 18-24 months.

**【CFO Financial Commentary】**
- **Earnings Performance**: Non-GAAP EPS of $2.58, driven by oncology and animal health growth. Full-year 2025 guidance: $64.5-65 billion revenue, $8.93-8.98 EPS (midpoint $8.96). 2026 outlook includes $25.9-26.4 billion operating expenses, reflecting pipeline investments.
- **Product Mix**: Gross margin 81.9% (up 1.4ppt) due to favorable product mix. ENFLONSIA initial stocking of $79 million, WINREVAIR sales $360 million. GARDASIL decline 25% (3% ex-China) due to Japan cohort expiration.
- **Risk Management**: 2026 headwinds include DIFICID and BRIDION generic entries, JANUVIA price impact. Offset by new launches (OHTUVAYRE, BRAVECTO QUANTUM) and pipeline expansion.

**【Q&A Highlights】**
- **Business Development**: CEO reaffirmed focus on $1-15 billion deals with scientific value. Verona Pharma deal exemplifies strategy to accelerate pipeline through strategic acquisitions.
- **Pipeline Progress**: Phase III enlicitide trial success (LDL reduction 58%) and tulisokibart expansion into dermatology/rheumatology. WELIREG Phase III data expected in 2026 for OS benefit in RCC.
- **Product Launches**: ENFLONSIA initial feedback positive, with $75 million VFC seeding order. KEYTRUDA QLEX adoption supported by commercial contracting strategy.
- **Policy Updates**: CEO optimistic about MFN negotiations with U.S. administration, aiming to lower patient costs while maintaining R&D investment sustainability.

Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript

- **Q2 Growth Drivers**: Oncology (+9% KEYTRUDA), Animal Health (+11%), and new products (WINREVAIR, CAPVAXIVE) offset GARDASIL China decline.
- **Pipeline Momentum**: WINREVAIR on track for $1B annual sales; enlicitide Phase III success positions for $15B cardiometabolic opportunity.
- **Strategic Initiatives**: $3B cost savings program to fund high-potential pipeline; Verona acquisition expands COPD portfolio.
- **H2 Outlook**: Return to 1-2% revenue growth, driven by oncology, Animal Health, and new product launches.
- **KEYTRUDA Transition**: Confident in pipeline to offset LOE; HIV, cardiometabolic, and oncology programs position for long-term growth.

**【CEO Opening Remarks】**
- Q2 2025 revenue of $15.8 billion, in line with expectations, driven by oncology, Animal Health, and new product launches (WINREVAIR, CAPVAXIVE). 
- WINREVAIR achieved $1 billion in cumulative sales within 15 months of launch.
- Announced multiyear optimization initiative to redirect $3 billion from lower-growth areas to high-potential pipeline programs.
- Confident in returning to growth in H2 2025, with 20+ new product growth drivers.
- Acquisition of Verona Pharma (Ohtuvayre for COPD) to expand cardiopulmonary portfolio.

**【CFO Financial Commentary】**
- Q2 GAAP net income: $420 million; Non-GAAP EPS: $2.13 (vs. $2.10 prior guidance).
- Gross margin: 82.2% (up 1.3ppt vs. prior quarter), driven by favorable product mix.
- Operating expenses: $6.6 billion (includes $200M Hengrui license charge).
- Full-year 2025 guidance: Revenue $64.3-65.3B (1-2% growth ex-FX), EPS $8.87-8.97.
- FY2025 outlook: Return to growth in H2, with oncology, Animal Health, and new products as key drivers.

**【Pipeline & R&D Updates】**
- **WINREVAIR**: Global sales $336M, 1,600+ new U.S. prescriptions. Japan launch expected Q3. HYPERION trial stopped early due to efficacy; ZENITH PDUFA date Oct 25.
- **Enlicitide**: Phase III CORALreef trials met endpoints, reducing LDL-C by 50-60%. Potential $15B cardiometabolic opportunity.
- **HIV Portfolio**: MK-8527 monthly dosing regimen shows rapid onset; doravirine/islatravir NDA under review.
- **Oncology**: 80+ Phase III studies across 13 tumor types; KEYTRUDA 10th earlier-stage approval.

**【Q&A Highlights】**
- **WINREVAIR Ex-U.S. Uptake**: Japan launch Q3, Europe reimbursement pending. Global PAH patient pool ~90,000, half outside U.S.
- **Restructuring Plan**: $3B cost savings (2025-2030) to reinvest in pipeline; operating expenses to grow with Phase III trials.
- **GARDASIL China**: No shipments through 2025; inventory elevated, demand soft. China sales <1% of total.
- **Business Development**: Focus on first-mover assets (e.g., Verona's Ohtuvayre); no impact from U.S.-China PDE3/4 collaboration.
- **KEYTRUDA IRA Impact**: Potential selection for 2029 price negotiation; confident in pipeline to offset LOE.


Merck & Co., Inc. (MRK) Q2 2025 Earnings Call Transcript

- **Q1 2025 Strong Execution**: $15.5B revenue driven by oncology (+6%), WINREVAIR ($280M), and CAPVAXIVE ($107M). 
- **Pipeline Powerhouse**: 2030 pipeline potential >$50B with 20+ new products; WINREVAIR Phase 3 data shows 76% mortality risk reduction. 
- **Tariff Resilience**: $12B+ U.S. manufacturing investments offset $200M 2025 tariff impact; inventory positions protect near-term. 
- **HIV Innovation**: doravirine/islatravir combo meets non-inferiority vs. Biktarvy in Phase 3; filing planned for mid-2025.

**【CEO Summary Section】**
- Q1 2025 revenue of $15.5 billion reflects 1% growth (excluding FX), driven by oncology, animal health, and new product launches (WINREVAIR, CAPVAXIVE). 
- $12B+ invested in U.S. manufacturing to mitigate tariffs; 2025 tariffs expected to cost $200M, but U.S. inventory positions mitigate near-term impact. 
- 2030 pipeline potential exceeds $50B, with 20+ new products in late-stage development. 
- Emphasis on AI investment to improve gross margin in H2 2025. 

**【CFO Financial Commentary】**
- GAAP net income $420M; Non-GAAP EPS $2.22 (vs. $2.23 prior guidance). 
- Oncology sales $7.2B (+6%), WINREVAIR $280M, CAPVAXIVE $107M. 
- Operating expenses $6.1B (-6% YoY), benefiting from disciplined pipeline investment. 
- Full-year 2025 guidance: $64.1-65.6B revenue, $8.82-8.97 EPS (excluding tariffs). 

**【Pipeline & R&D Updates】**
- WINREVAIR Phase 3 ZENITH trial shows 76% risk reduction in PAH mortality; Hyperion trial halted early due to overwhelming efficacy. 
- HIV doravirine/islatravir combo meets non-inferiority vs. Biktarvy in Phase 3. 
- CAPVAXIVE approved in Europe; GARDASIL 9 male indication approved in China. 

**【Key Q&A Themes】**
- **Tariff Mitigation**: U.S. manufacturing investments ($12B+ since 2018) and inventory management protect against tariffs. 
- **Long-Term Growth**: 2030 pipeline value >$50B; 20+ new products in late-stage. 
- **GARDASIL China Challenges**: Elevated inventories and soft demand; 2025 outlook cautious. 
- **KEYTRUDA Post-LOE Strategy**: Pipeline diversification (e.g., subQ pembrolizumab) positions for post-2028 growth.

Merck & Co. (MRK)-24 Apr 25-2025 Q1 Earnings call transcript

- **Revenue Resilience**: 2024 revenue up 7% to $15.6B, driven by oncology (+21% for KEYTRUDA) and Animal Health (+13%).\n- **GARDASIL China Reset**: Temporarily paused shipments to reduce inventory, with 2025 China sales guidance of $0-1B.\n- **WINREVAIR Growth**: CEO confident in 100%+ YoY sales growth, with 5,200+ new patients prescribed.\n- **Pipeline Power**: 20+ Phase 3 assets with $50B+ potential, including oral PCSK9, TROP2 ADC, and HIV combo therapies.\n- **2025 Outlook**: $64.1-65.6B revenue (+2-4% YoY), $8.88-9.03 EPS, with Medicare Part D redesign impacting $400M.\n

**【CEO Opening Remarks】**
- **2024 Performance Overview**: Rob Davis highlighted strong growth driven by oncology (KEYTRUDA), Animal Health, and new product launches, despite GARDASIL headwinds in China. Total revenue reached $15.6B (+7% YoY).\n- **GARDASIL China Strategy Adjustment**: Temporarily paused shipments to China to reduce elevated inventory, with no shipments expected through mid-2025. Long-term confidence in China remains due to unvaccinated populations.\n- **Pipeline Strength**: 20 potential new growth drivers, including WINREVAIR and CAPVAXIVE, with $50B+ pipeline potential.\n- **KEYTRUDA LOE Preparedness**: Confident in navigating 2028 patent expiry with diversified pipeline and new launches.\n
**【CFO Financial Highlights】**
- **Revenue Breakdown**:\n  - Oncology: KEYTRUDA ($7.8B, +21%), WELIREG (+100%).\n  - Vaccines: GARDASIL ($1.6B, -18% due to China), CAPVAXIVE ($50M).\n  - Cardiovascular: WINREVAIR ($200M, early-stage launch).\n  - Animal Health: +13% growth.\n- **Financial Metrics**:\n  - Gross Margin: 80.8% (up 3.6pts vs. prior year).\n  - Operating Expenses: $7.4B (-10% YoY, excluding one-time charges).\n  - EPS: $1.72 (non-GAAP).\n- **2025 Guidance**:\n  - Revenue: $64.1-65.6B (+2-4% YoY, excluding FX).\n  - EPS: $8.88-9.03.\n  - GARDASIL China: $0-1B (low-end assumes no shipments).\n
**【CFO on Key Initiatives】**\n- **WINREVAIR Momentum**: 5,200+ new patients prescribed, 80% adherence rate.\n- **Pipeline Investment**: $25.4-26.4B in R&D expenses to support 20+ Phase 3 trials.\n- **Dividend & Share Buybacks**: Committed to dividend growth; $12B share repurchase authorization.\n
**【Q&A Highlights】**\n- **WINREVAIR Growth Confidence**: Rob reaffirmed 100%+ YoY growth target, citing strong January trends.\n- **GARDASIL Long-Term Outlook**: Withdrew $11B target due to China uncertainty, but ex-China growth remains intact.\n- **Policy Risks**: Medicare Part D redesign expected to impact WINREVAIR and oral oncology (+$400M headwind).\n- **Pipeline Updates**:\n  - Oral PCSK9 (enlicitide): 3 Phase 3 trials set for 2025 readouts.\n  - TROP2 ADC (Sac-TMT): 10 Phase 3 trials ongoing across solid tumors.\n  - HIV Combination Therapies: doravirine/islatravir Phase 3 data pending.\n

Actual																	1.4303	1.3063	1.6591	1.2587	1.3349	1.31	1.75	1.8	2.14	1.87	1.85	1.62	1.4	-2.06	2.13	0.03	2.07	2.28	1.57	1.72	2.22	2.13	2.58	2.04
Forecast																	1.2797	1.0112	1.3728	1.3204	1.5348	1.3092	1.5458	1.5263	1.8255	1.704	1.7055	1.5349	1.3212	-2.1805	1.9534	-0.1085	1.8855	2.1679	1.484	1.6093	2.1327	2.0331	2.3624	2.0113
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+11.77%	+29.18%	+20.86%	-4.67%	-13.02%	+0.06%	+13.21%	+17.93%	+17.23%	+9.74%	+8.47%	+5.54%	+5.96%	+5.53%	+9.04%	+127.65%	+9.79%	+5.17%	+5.80%	+6.88%	+4.09%	+4.77%	+9.21%	+1.43%

Actual	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	12.06B	10.87B	12.55B	12.51B	12.08B	11.40B	13.15B	13.52B	15.90B	14.59B	14.96B	13.83B	14.49B	15.04B	15.96B	14.63B	15.78B	16.11B	16.66B	15.62B	15.53B	15.81B	17.28B	16.40B
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	11.48B	10.40B	12.21B	12.67B	12.61B	11.23B	12.32B	13.16B	14.56B	13.86B	14.07B	13.66B	13.79B	14.44B	15.30B	14.49B	15.21B	15.87B	16.47B	15.48B	15.34B	15.86B	16.98B	16.20B
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+5.07%	+4.52%	+2.77%	-1.25%	-4.17%	+1.55%	+6.79%	+2.78%	+9.24%	+5.32%	+6.35%	+1.26%	+5.03%	+4.11%	+4.35%	+0.97%	+3.75%	+1.53%	+1.11%	+0.91%	+1.24%	-0.37%	+1.75%	+1.24%

MRK

MRK fundamentals

MRK Q4 2025 Earnings

Earnings Call

You can ask Aime

MRK

MRK fundamentals

MRK Q4 2025 Earnings

Earnings Call

MRK Earnings Call Summary for Q4/20259:00 AM on Feb 3, 2026

MRK Earnings Call Summary for Q3/20259:00 AM on Oct 30, 2025

MRK Earnings Call Summary for Q2/20259:00 AM on Jul 29, 2025

MRK Earnings Call Summary for Q1/20259:00 AM on Apr 24, 2025

MRK Earnings Call Summary for Q4/20249:00 AM on Feb 4, 2025

You can ask Aime